Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05536804 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Name: A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes — clinical trial record (NCT05536804)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: TREASURE-CKD

StatusCompleted

PhasePhase 2

SponsorEli Lilly and Company

Started2023-02-08

View on ClinicalTrials.gov ↗

We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.

Amendment history 2 changes detected by DataLookout

2026-09-12

Trial completed

2026-09-12

Primary completion confirmed: July 2026 (last estimated September 2026)

Trial Details

NCT Number	NCT05536804
Lead Sponsor	Eli Lilly and Company
Conditions	Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
Enrollment	134 participants
Start Date	2023-02-08
Primary Completion	2026-07-06 (estimated)
Study Completion	2026-07-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-11